Pre-registered attendees can obtain materials.Those who have not yet registered may do so.

• Emerging Targets

Emerging molecular therapies in breast cancer
José Baselga, MD
Vall d’Hebron University Hospital
Barcelona, SPAIN

Disrupting IGF signaling in breast cancer as a therapeutic strategy
Douglas Yee, MD
University of Minnesota
Minneapolis, MN

• Signal Transduction Pathways Controlling Proliferation and Death in
  Breast Cancer

Proliferative signaling by transforming oncogenes: Relevance to current and new therapeutic agents
Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Harnessing apoptosis to kill breast cancer cells
Anthony Letai, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

• Clinical Trials 101

Information for basic and translational researchers

Susan Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Cancer clinical trials in the 21st century: the need for a paradigm shift in design, conduct, and support
Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM

• Pathobiology

Pathobiology: When the tumor is the target

Andrea Richardson, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

TBA
Lisa Carey, MD
University of North Carolina
Chapel Hill, NC